Navigation Links
Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
Date:6/23/2009

HUNTINGTON BEACH, California and AMSTERDAM, June 23 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the inclusion of its breast cancer recurrence test MammaPrint in St. Gallen's 2009 International Expert Consensus on the primary therapy of early breast cancer. The recommendations have been published online in the Annals of Oncology and will appear in the August print edition.

The St. Gallen expert panel consists of key opinion leaders from across Europe (53%), the United States (33%), and rest of the world (14%). In the recently published article highlighting the 2009 recommendations, the panellists emphasize that "in an important change from the previous St. Gallen conference...the Panel supported the use of a validated multigene- profiling assay, if readily available, as an adjunct to high-quality phenotyping of breast cancer in cases in which the indication for adjuvant chemotherapy remained uncertain."

In addition, the panel cautioned that so-called intermediate scores are not useful in clinical decision making. Currently, MammaPrint is the only breast cancer recurrence assay available that accurately yields a binary result, without an intermediate group, addressing the panel's recommendations. The FDA-cleared assay is always clinically useful and indicates whether a patient is at low or high risk for metastasis and the resulting clarity is vital in helping physicians personalize treatment options.

"St. Gallen's guideline inclusion is a key step in further establishing MammaPrint as a standard of care. It also supports our commitment to upholding rigorous standards of quality and efficacy," said Dr. Bernhard Sixt, Agendia's President and Chief Executive Officer. "With MammaPrint we aim to provide breast cancer patients and their physicians with definitive answers to crucial treatment questions."

In addition to MammaPrint, the company also offers TargetPrint to further improve breast cancer treatment options. TargetPrint quantitatively determines the gene expression levels of HER2neu, estrogen and progesterone receptors. Ongoing research and development efforts continue to augment Agendia's ability to accurately predict breast cancer recurrence, and help physicians tailor individual treatment plans to their patients.

    For online access to the Annals of Oncology:
http://annonc.oxfordjournals.org/cgi/content/full/mdp322v1

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatment within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer therapy. The company markets four products, with several new genomic tests in development. Agendia collaborates with pharmaceutical companies in the development of highly effective personalized drugs in the area of oncology and was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands. For more information please visit http://www.agendia.com.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer
2. Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
3. New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer
4. New Research Shows Antidepressants May Thwart Breast Cancer Treatment
5. Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy
6. New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
7. Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women
8. Hooters of Orange Park to Host Charity Car Wash Raising Money for Breast Cancer Research
9. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
10. Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
11. ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
(Date:1/19/2017)... , Jan. 19, 2017 ViewRay, Inc. ... a federal institution supporting research in Germany ... and patient treatments at the University Clinic Heidelberg as ... The MRIdian Linac program will be headed by ... also heads radiation oncology at the German Cancer Research ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017   Science ... is excited to announce that the first five ... Biology  (RP:CB) have been published in eLife today. ... project represents the first practical evaluation of reproducibility ... in reproducible studies. Unlike other assessments of reproducibility, ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and ... essential oils, announced the company had a successful visit to the 2017 ECRM Diet, ... gives companies that work in the nutritional, sports and health industries a chance to ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... International ... of nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in ... bodybuilder and nutritional scientist who was determined to create a line of products that ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and earnest tale ... each of his children. “The Angel” is the creation of published author, Marjorie Lund-Fontaine, ... City, and impassioned writer. , When asked of her new book, Marjorie says, “‘The ...
(Date:1/20/2017)... ... ... to Christmas:” a beautiful and enchanting tale that teaches children the true meaning of Christmas. ... in Oklahoma City, and a devoted woman of faith. , “Becoming a parent changes ... back of my mind for years, but actually doing it might have been a while ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... E-learning system for Clinical and Regulatory education for Physicians, Physician Advisors, Case ... successful education methodology of Disease Specific Documentation Improvement. , The Aerolib Learning ...
Breaking Medicine News(10 mins):